[Clinical study on HK 2 (Hylakombun) in gastrointestinal diseases].
D000328:Adult; D004415:Dyspepsia / Q000188:drug therapy; D005260:Female; D005414:Flatulence / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D008049:Lipase / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010194:Pancreatin / Q000008:administration & dosage*; D010208:Papaverine / Q000008:administration & dosage*; D011178:Postgastrectomy Syndromes / Q000188:drug therapy; D011804:Quinolines / Q000008:administration & dosage*
D011804:Quinolines; D010194:Pancreatin; D010208:Papaverine; D008049:Lipase
Klinische Prüfung von HK 2 (Hylakombun) bei gastrointestinalen Erkrankungen.